Falls Risk in Long-Term Care Residents With Cognitive Impairment: Effects of COVID-19 Pandemic.

OBJECTIVES: The aim of this study was to investigate the impact of the COVID-19 pandemic on falls rates in long-term care residents with cognitive impairment. DESIGN: An observational study using routinely collected national interRAI data. SETTING AND PARTICIPANTS: Participants were from long-term care residents (age ≥60 years) who received an interRAI Long Term Care Facility assessment anywhere in New Zealand between August 17, 2018, and August 16, 2022. METHODS: The primary outcome was "At least 1 fall in the last 30 days." Based on the Cognitive Performance Scale (CPS), cognitive impairment was categorized into 3 levels: intact or borderline intact (0-1), mild to moderate impairment (2-3), and moderately to very severe impairment (4-6). The COVID-19 pandemic was divided into 3 periods (First wave: March 21, 2020, to June 8, 2020; Varying level of community outbreaks: June 9, 2020 to August 16, 2021; and Delta-Omicron wave: August 17, 2021, to August 16, 2021) and compared to a pre-COVID-19 period (August 17, 2018, to March 20, 2020). Cox regression modeling was used to study falls and interactions between CPS and COVID-19 pandemic periods, along with other established falls risk factors in the literature. RESULTS: A total of 282,518 interRAI-LTCF assessments from 75,132 unique residents were included. Interactions between CPS and COVID-19 pandemic periods found that cognitive impairment was associated with a higher hazard ratio (ranged from 1.22 to 1.37) in each of the 3 COVID-19 pandemic periods. We also found unstable health, unsteady gait, wandering, and moderate to severe ADL dependency were the strongest risk factors for falls. CONCLUSIONS AND IMPLICATIONS: Cognitively impaired long-term care residents had an increased risk for falls during the COVID-19 pandemic. This risk was influenced by several factors. In future pandemic or infection control related isolation, residents who are most at risk can be identified for targeted falls prevention programs.

Impacts of the COVID-19 lockdown on self-reported mood and self-rated health of community-dwelling adults with chronic illness.

AIM: To determine whether self-reported mood or self-rated health were affected in community-dwelling adults with chronic illness following COVID-19 lockdown. METHODS: This was a repeated cross-sectional study using secondary data. We included New Zealanders aged 40+ who underwent International Residential Instrument (interRAI) assessments in the year prior to COVID-19 lockdown (25 March 2019-24 March 2020) or in the year following COVID-19 lockdown (25 March 2020-24 March 2021). Pairwise comparisons were made between each pre-lockdown quarter and its respective post-lockdown quarter to account for seasonality patterns. Data from 45,553 (pre-lockdown) and 45,349 (post-lockdown) assessments were analysed. Outcomes (self-reported mood, self-rated health) were stratified by socio-demographic variables. RESULTS: Self-reported mood improved in the first quarter post-lockdown among those aged 80+, as well as among women, people of European ethnicity, those living alone and those living in more deprived areas. Self-rated health improved in these same groups, as well as among those aged 65-79, and among men. No differences in self-reported mood or self-rated health were found in the second, third, or fourth quarters post-lockdown. CONCLUSIONS: Self-reported mood and self-rated health of community-dwelling adults with chronic illness were not negatively affected following COVID-19 lockdown, and temporarily improved among some sub-groups. However, the longer-term impacts of the COVID-19 pandemic need to be closely monitored.

Anti-dementia medication use in Aotearoa New Zealand: An exploratory study using health data from the Integrated Data Infrastructure (IDI).

OBJECTIVE: Anti-dementia medications such as acetylcholinesterase inhibitors are an important part of the management pathway for dementia. However, there are limited data in New Zealand that have examined the rates and patterns of use of funded anti-dementia medication and how use differs with ethnicity, age and sex. METHODS: This was a retrospective population-based descriptive study. Using the Integrated Data Infrastructure, we identified individuals of all ages coded for a diagnosis of dementia and estimated the proportion dispensed funded anti-dementia medication - donepezil tablets and rivastigmine patches - between 1 July 2016 and 30 June 2020. Rates of medication use in five main ethnic groups (Maori, Pacific peoples, Asian, European, and Middle Eastern, Latin American and African) in the <65, 65-79 and 80 and over (80+) age groups were compared and also between males and females in all sub-groups. Log-binomial models were used to calculate relative risks to determine any differences in anti-dementia medication use in the five ethnic groups and the three age groups and between males and females in each of the four study years. RESULTS: Overall, one-third of the dementia population received a funded anti-dementia medication in the total population (all ages) between 2016 and 2020. Donepezil tablets were dispensed in 31.6-34.0% and rivastigmine patches in 1.4-2.1% across the four study years. Compared to people of European ethnicity, Maori, Pacific peoples, and Middle Eastern, Latin American and African groups were less likely to be dispensed an anti-dementia medication (Maori: relative risk = 0.79-0.81, p < 0.0001; Pacific peoples: relative risk = 0.72-0.74, p < 0.0001; Middle Eastern, Latin American and African: relative risk = 0.73-0.78, p < 0.05). Compared to the age 80+ group, the 65-79 age group was more likely (relative risk = 1.50-1.54, p < 0.0001), while the age <65 group was less likely (relative risk = 0.67-0.71, p < 0.0001) to be dispensed an anti-dementia medication. There were no statistically significant differences in anti-dementia medication use between males and females. CONCLUSION: This study provides important information about funded anti-dementia medication use in New Zealand and how this differs by ethnicity, age and sex. Despite higher dementia prevalence in Maori and Pacific peoples, these groups were less likely to receive funded anti-dementia medication.

Incidence of Young Onset Dementia in Waikato, New Zealand: A Population-Based Study.

BACKGROUND: There is limited epidemiological research on the incidence of young onset dementia (YOD). Estimates of YOD incidence in New Zealand are extrapolated from international studies that do not reflect New Zealand's population and ethnic diversity. OBJECTIVE: To determine the incidence of YOD in the geographical area served by the Waikato District Health BoardMethods: All new inpatient and outpatient in the age range 30-64 years with a documented diagnosis of dementia at Waikato Hospital between 1 January 2014 -31 December 2016 were identified. Incidence rates were calculated by 5-year age-band, sex, and ethnicity. RESULTS: 64 incident cases of YOD were included. Incidence rates for all cause YOD were 13.3 (95% CI 10.3-17.0) and 22.7 (95% CI 17.5-29.1) per 100,000 person-years in the age range 30-64 years and 45-64 years respectively. The incidence rate in Maori (20.0, 95% CI 11.4-32.4) was higher compared to non-Maori (12.0, 95% CI 8.9-15.9), but this difference was not statistically significant (p = 0.09). CONCLUSION: The incidence of YOD in this study is similar to global estimates. Incidence may be higher in Maori compared to non-Maori, highlighting the need for culturally appropriate approaches to dementia prevention, intervention, and care.

Prevalence of young-onset dementia: nationwide analysis of routinely collected data.

INTRODUCTION: Young-onset dementia prevalence is understudied internationally. Previous studies have been limited by low case numbers, reliance on single sources of routinely collected health data for case identification and inclusion of a limited age range. Our objective was to determine the 1-year period prevalence of diagnosed dementia in people aged 0-64 in the entire New Zealand population using routinely collected health data. METHODS: A population-based descriptive study was carried out in New Zealand (population 4.8 million) using routinely collected deidentified health data from 2016 to 2020. Dementia cases in seven linked health datasets in the New Zealand Integrated Data Infrastructure were identified using diagnostic codes and/or use of antidementia medication. Prevalence for each of the four study years was calculated by age, sex and ethnicity. RESULTS: From a total population of 4 027 332-4 169 754 individuals aged 0-64, we identified 3396-3474 cases of 'all-cause' dementia in each of the study years (prevalence crude range: 83-84/100 000 people aged 0-64; 139-141/100 000 people aged 30-64 years; 204-207/100 000 people aged 45-64 years). Age-standardised prevalence was higher in males than females. Age-standardised and sex-standardised prevalence was higher in Maori and Pacific People than European and Asian. DISCUSSION: By using a large study population and multiple national health datasets, we have minimised selection bias and estimated the national prevalence of diagnosed young-onset dementia with precision. Young-onset dementia prevalence for the total New Zealand population was similar to reported global prevalence, validating previous estimates. Prevalence differed by ethnicity, which has important implications for service planning.

Prioritising a culturally safe e-Mental Health research agenda in Aotearoa New Zealand: A sector survey report.

OBJECTIVE: To collect mental health and addiction service providers' opinions about priorities for an e-Mental Health (eMH) research agenda focused on delivering culturally safe eMH in Aotearoa New Zealand. METHOD: Service providers were recruited to participate in an anonymous online survey, which asked participants to rate the importance of potential research domains and items on a continuous scale from 1 to 10. The mean values of each item were normalised to develop a priority index. RESULTS: 48 participants rated at least one of the listed research items. The highest-rated items were (i) identifying strategies to improve access; co-developing eMH with the community (ii) a set of competencies required for delivering culturally safe care, (iii) a set of meaningful clinical outcomes that can be achieved via eMH, (iv) guidelines for the delivery of eMH services and (v) investigating the extent to which eMH could meet the mental health needs of these communities. 'Standards and guidelines' was the domain with the highest priority index. CONCLUSIONS: Mental health and addiction service providers in Aotearoa New Zealand prioritised an eMH research agenda that is focused on pro-equity outcomes and incorporating the voices and experiences of the communities they seek to serve.

Adaptation models, barriers, and facilitators for cultural safety in telepsychiatry: A systematic scoping review.

Introduction: Indigenous peoples, and racial and ethnic minorities around the world experience significant mental health inequities. Telepsychiatry can contribute to addressing these inequities among these populations. However, it is first crucial to ensure the cultural safety of this tool as a critical step toward health equity. This review aimed to collate evidence regarding cultural adaptations, barriers, opportunities, and facilitators for telepsychiatry services supporting minority groups. Method: Using the PRISMA extension for scoping reviews (PRISMA-ScR) guideline, we conducted a systematic scoping review and thematic analysis. Six databases were searched using the PICO framework, i.e., population, intervention, comparison, and outcomes.. Additional literature was identified through reference lists screening. We developed a table for data extraction, and the extracted data were further analyzed following Braun and Clarke's approach for thematic analysis. Results: A total of 1514 citations were screened with a final total of 58 articles included in the review. The themes related to telepsychiatry cultural adaptations emphasize the crucial role of community involvement and quality service delivery. Identified barriers were associated with service and infrastructure, and service users' socioeconomic and cultural contexts. Opportunities and facilitators for telepsychiatry were enhanced access and rapport, and multi-organizational collaborations and partnerships. Discussion: This review identified factors that can guide the adaptation of telepsychiatry evidence-based interventions to meet the needs of Indigenous peoples and racial and ethnic minorities. Telepsychiatry programs must be specifically designed for the population they seek to serve, and this review offers emerging insights into critical factors to consider in their development.

Impact of the first wave of COVID-19 on the health and psychosocial well-being of Maori, Pacific Peoples and New Zealand Europeans living in aged residential care.

OBJECTIVE: To investigate the impact of New Zealand's (NZ) first wave of COVID-19, which included a nationwide lockdown, on the health and psychosocial well-being of Maori, Pacific Peoples and NZ Europeans in aged residential care (ARC). METHODS: interRAI assessments of Maori, Pacific Peoples and NZ Europeans (aged 60 years and older) completed between 21/3/2020 and 8/6/2020 were compared with assessments of the same ethnicities during the same period in the previous year (21/3/2019 to 8/6/2019). Physical, cognitive, psychosocial and service utilisation indicators were included in the bivariate analyses. RESULTS: A total of 538 Maori, 276 Pacific Peoples and 11,322 NZ Europeans had an interRAI assessment during the first wave of COVID-19, while there were 549 Maori, 248 Pacific Peoples and 12,367 NZ Europeans in the comparative period. Fewer Maori reported feeling lonely (7.8% vs. 4.5%, p = 0.021), but more NZ Europeans reported severe depressive symptoms (6.9% vs. 6.3%, p = 0.028) during COVID-19. Lower rates of hospitalisation were observed in Maori (7.4% vs. 10.9%, p = 0.046) and NZ Europeans (8.1% vs. 9.4%, p < 0.001) during COVID-19. CONCLUSIONS: We found a lower rate of loneliness in Maori but a higher rate of depression in NZ European ARC populations during the first wave of COVID-19. Further research, including qualitative studies with ARC staff, residents and families, and different ethnic communities, is needed to explain these ethnic group differences. Longer-term effects from the COVID-19 pandemic on ARC populations should also be investigated.

Dementia prevalence estimation among the main ethnic groups in New Zealand: a population-based descriptive study of routinely collected health data.

OBJECTIVE: Estimates of dementia prevalence in New Zealand (NZ) have previously been extrapolated from limited Australasian studies, which may be neither accurate nor reflect NZ's unique population and diverse ethnic groups. This study used routinely collected health data to estimate the 1-year period prevalence for diagnosed dementia for each of the 4 years between July 2016 and June 2020 in the age 60+ and age 80+ populations and for the four main ethnic groups. DESIGN: A population-based descriptive study. SETTING: Seven national health data sets within the NZ Integrated Data Infrastructure (IDI) were linked. Diagnosed dementia prevalence for each year was calculated using the IDI age 60+ and age 80+ populations as the denominator and also age-sex standardised to allow comparison across ethnic groups. PARTICIPANTS: Diagnosed dementia individuals in the health datasets were identified by diagnostic or medication codes used in each of the data sets with deduplication of those who appeared in more than one data set. RESULTS: The crude diagnosed dementia prevalence was 3.8%-4.0% in the age 60+ population and 13.7%-14.4% in the age 80+ population across the four study years. Dementia prevalence age-sex standardised to the IDI population in the last study period of 2019-2020 was 5.4% for Maori, 6.3% for Pacific Islander, 3.7% for European and 3.4% for Asian in the age 60+ population, and 17.5% for Maori, 22.2% for Pacific Islander, 13.6% for European and 13.5% for Asian in the age 80+ population. CONCLUSIONS: This study provides the best estimate to date for dementia prevalence in NZ but is limited to those people who were identified as having dementia based on data from the seven included data sets. The findings suggest that diagnosed dementia prevalence is higher in Maori and Pacific Islanders. A nationwide NZ community-based dementia prevalence study is much needed to confirm the findings of this study.

Differences in the potential for dementia prevention between major ethnic groups within one country: A cross sectional analysis of population attributable fraction of potentially modifiable risk factors in New Zealand.

BACKGROUND: Twelve potentially modifiable risk factors (less education, hypertension, obesity, alcohol, traumatic brain injury (TBI), hearing loss, smoking, depression, physical inactivity, social isolation, diabetes, air pollution) account for an estimated 40% of worldwide dementia cases. We aimed to calculate population attributable fractions (PAFs) for dementia for the four largest New Zealand ethnic groups (European, Maori, Asian, and Pacific peoples) to identify whether optimal dementia prevention targets differed by ethnicity. METHODS: We calculated risk factor prevalence for 10 risk factors using the New Zealand Health Survey 2018/19 and published reports for hearing loss and TBI prevalences. We calculated the PAF for each risk factor using calculated prevalence and relative risk estimates from previous meta-analyses. To account for risk factor overlap, we calculated communality of risk factors and a weighted PAF. FINDINGS: The weighted PAF for dementia was 47.7% overall in New Zealand, 47.6% for Europeans, 51.4% for Maori, 50.8% for Pacific peoples, and 40.8% for Asians. Highest PAFs for Europeans were hearing loss (8%) and social isolation (5.7%), and for Asians hearing loss (7.3%) and physical inactivity (5.5%). For Maori and Pacific peoples, highest PAFs were for obesity (7.3% and 8.9% respectively) and hearing loss (6.5% and 6.6%). INTERPRETATION: New Zealand has higher dementia prevention potential than worldwide estimates with high prevalences of untreated hearing loss and obesity. The relative contribution of individual risk factors PAFs varies by ethnic group. Public health strategies for dementia prevention need to be tailored to these differences. FUNDING: Health Research Council of New Zealand (HRC:20/021).

Antipsychotic and sedative medication use in long-term care facilities providing dementia care.

AIM: This study aimed to quantify use of antipsychotic and sedative medications in residents with dementia in long-term care facilities in the Waikato District Health Board (DHB) catchment and to identify factors associated with the prescription of these medications. METHODS: Resident records and the medication charts of 271 residents with a diagnosis of dementia from 13 dementia units in the Waikato DHB catchment, as well as the psychogeriatric (PG) unit, were reviewed for current prescriptions for any antipsychotic or sedative medication and the date those medications were most recently prescribed. RESULTS: Antipsychotics were prescribed for 133 (49.1%) residents, with a mean (95% CI) of 401 (354-448) days since the most recent prescription was made. Only 16.8% of antipsychotic prescriptions were prescribed in the preceding 12 weeks, with 31.3% of prescriptions prescribed more than a year prior. Residents were more likely to be prescribed an antipsychotic if they were male (56.9% vs 42.6%, p=.019) or had an incident form completed (30.8% vs 19.6% p=.03). Regression analysis showed only gender (OR 1.79, 95%CI 1.07-2.98, p=.026) was associated with antipsychotic medication prescription. Sedatives were prescribed for 60 (22.1%) residents, with a mean (95%CI) of 487 (431-544) days since the most recent prescription was made, and 44.8% of prescriptions were dated more than a year prior. Residents were more likely to be prescribed a sedative if they entered the facility at a younger age (76.9 vs 79.5, p=.042) or had been in the current facility longer (980 vs 734 days, p=.048). Following regression analysis, no individual factors were significantly associated with sedative prescription. CONCLUSION: With clear evidence of the risks of antipsychotics to patients with dementia, the proportion of residents prescribed an antipsychotic or sedative in this study, in conjunction with the prolonged duration of prescription, is cause for concern and needs addressing.

Living with Dementia in Aotearoa (LiDiA): a cross-sectional feasibility study protocol for a multiethnic dementia prevalence study in Aotearoa/New Zealand.

INTRODUCTION: Aotearoa/New Zealand (NZ) is officially recognised as a bicultural country composed of Maori and non-Maori. Recent estimations have projected a threefold increase in dementia prevalence in NZ by 2050, with the greatest increase in non-NZ-Europeans. The NZ government will need to develop policies and plan services to meet the demands of the rapid rise in dementia cases. However, to date, there are no national data on dementia prevalence and overseas data are used to estimate the NZ dementia statistics. The overall aim of the Living with Dementia in Aotearoa study was to prepare the groundwork for a large full-scale NZ dementia prevalence study. METHODS AND ANALYSIS: The study has two phases. In phase I, we will adapt and translate the 10/66 dementia assessment protocol to be administered in Maori, Samoan, Tongan and Fijian-Indian elders. The diagnostic accuracy of the adapted 10/66 protocol will be tested in older people from these ethnic backgrounds who were assessed for dementia at a local memory service. In phase II, we will address the feasibility issues of conducting a population-based prevalence study by applying the adapted 10/66 protocol in South Auckland and will include NZ-European, Maori, Samoan, Tongan, Chinese and Fijian-Indian participants. The feasibility issues to be explored are as follows: (1) how do we sample to ensure we get accurate community representation? (2) how do we prepare a workforce to conduct the fieldwork and develop quality control? (3) how do we raise awareness of the study in the community to maximise recruitment? (4) how do we conduct door knocking to maximise recruitment? (5) how do we retain those we have recruited to remain in the study? (6) what is the acceptability of study recruitment and the 10/66 assessment process in different ethnic groups? ETHICS AND DISSEMINATION: The validity and feasibility studies were approved by the New Zealand Northern A Health and Disability Ethics Committee (numbers 17NTA234 and 18NTA176, respectively). The findings will be disseminated through peer-reviewed academic journals, national and international conferences, and public events. Data will be available on reasonable request from the corresponding author.

Impact of COVID-19 on the health and psychosocial status of vulnerable older adults: study protocol for an observational study.

BACKGROUND: Many countries around the world have adopted social distancing as one of the public health measures to reduce COVID-19 transmissions in the community. Such measures could have negative effects on the mental health of the population. The aims of this study are to (1) track the impact of COVID-19 on self-reported mood, self-rated health, other health and psychosocial indicators, and health services utilization of people who have an interRAI assessment during the first year of COVID-19; (2) compare these indicators with the same indicators in people who had an interRAI assessment in the year before COVID-19; and (3) report these indicators publicly as soon as data analysis is completed every 3 months. METHODS: interRAI COVID-19 Study (iCoS) is an observational study on routinely collected national data using the interRAI Home Care and Contact Assessment, which are standardized geriatric assessment tools mandated for all people assessed for publicly funded home support services and aged residential care in New Zealand. Based on the 2018/19 figures, we estimated there are 36,000 interRAI assessments per annum. We will compare the four post-lockdown quarters (from 25th March 2020) with the respective pre-lockdown quarters. The primary outcomes are self-reported mood (feeling sad, depressed or hopeless: 0 = no, 1 = yes) and self-rated health (0 = excellent, 1 = good, 2 = fair, 3 = poor). We will also analyze sociodemographics, other secondary health and psychosocial indicators, and health services utilization. Descriptive statistics will be conducted for primary outcomes and other indicators for each of the eight quarters. We will compare the quarters using regression models adjusted for demographic characteristics using weights or additional variables. Key health and psychosocial indicators will be reported publicly as soon as data analysis is completed for each quarter in the 12-month post-lockdown period by using a data visualization tool. DISCUSSION: This rapid translation of routinely collected national interRAI data will provide a means to monitor the health and psychosocial well-being of vulnerable older New Zealanders. Insights from this study can be shared with other countries that use interRAI and prepare health and social services for similar epidemics/pandemics in the future.

Ability of the Maze Navigation Test, Montreal Cognitive Assessment, and Trail Making Tests A & B to predict on-road driving performance in current drivers diagnosed with dementia.

AIM: This study aimed to evaluate the ability of the Maze Navigation Test (MNT), Montreal Cognitive Assessment (MoCA) and Trail Making Tests A & B (TMT A & B) to predict on-road driving performance in current drivers diagnosed with dementia. METHODS: Current drivers with a diagnosis of dementia in whom there were clinical concerns about their driving safety were invited to participate between December 2014 and February 2018. Participants completed the MNT, MoCA and TMT A & B, then underwent a blinded specialist Occupational Therapy & Rehabilitation Service (OTRS) off-road and on-road driving assessment. RESULTS: Of the 34 participants, 19 (55.9%) retained their full license and 15 (44.1%) received driving restrictions (including cessation). Only completion time for the MNT (AUC .737, p=.019), the MoCA domain of attention (AUC .809, p=.003) and a combination of the MoCA domain of attention and visuospatial/executive (AUC .783, p=.006) predicted outcome. Derived optimal cut-scores were <443s for MNT completion time (sensitivity 73.3%, specificity 68.4%), <5/6 for MoCA-attention (sensitivity 73.3%, specificity 72.2%) and <8/11 for MoCA-visuospatial/executive+attention (sensitivity 80%, specificity 66.7%). Using these derived cut-scores, MNT completion time predicted poor performance during the on-road assessment in the domains of speed control (p=.039), planning/judgement (p=.004) and vehicle position (p=.028). CONCLUSION: Results of this study indicate MNT completion time and the MoCA domains of attention and visuospatial/executive could be used to inform driving ability and further referral for a specialist driving assessment.

Performance of the Maze Navigation Test in a sample of older New Zealanders.

OBJECTIVE: It is often difficult to assess the driving performance of people with mild dementia. The Maze Navigation Test (MNT) was developed in the USA and has been shown to predict driving performance. The aim of this study is to evaluate how the MNT is performed against three commonly used bedside cognitive screening tools and compare our findings with the US population. METHODS: A convenience sample of 42 cognitively intact older people (age ≥65) completed the MNT, Mini-Mental State Examination, the revised Addenbrooke's Cognitive Examination and the Trail Making Tests. RESULTS: The mean MNT completion time was 307.6 (SD=85.6) and 444.5 (SD=157.3) for the 65-74 years and 75-84 years age group, respectively. Pearson's product-moment correlations were strongest with the Trail Making Test Part B (r=0.602). CONCLUSIONS: The findings of this study were comparable with the initial US data. The MNT is an easy-to-administer bedside cognitive screening tool. Further validation studies using the MNT and driving performance are warranted.

Stresses experienced by psychiatrists and their role in burnout: a national follow-up study.

BACKGROUND: Many studies have looked at sources of stress in psychiatrists, yet the role played by different factors in the causation of burnout in psychiatrists remains unclear. We had two aims, first, to develop a predictive model for the onset of burnout. Second, we aimed to study the differences in the perception of what caused stress between psychiatrists who rated themselves high on Emotional Exhaustion compared to those who rated themselves as low on Emotional Exhaustion. METHODS: A previously described questionnaire that identified stressors relevant to consultant psychiatrists was mailed out to 426 psychiatrists, with 240 replies. Scores on the Emotional Exhaustion dimension of the Maslach Burnout Inventory were available for 131 respondents. RESULTS: Based on an earlier literature review, the Sources of Stress Questionnaire (SOS-Q) used in the study had 45 factors, categorized into predisposing, precipitating, perpetuating and protective factors for burnout in psychiatrists. Of these, factor analysis identified 11 non-correlated factors which were used in the final analysis of this study. Four factors emerged as associated with burnout in psychiatrists in New Zealand: too much work; working long hours; an aggressive administrative environment; and lacking support from management. Two factors negatively correlated with Emotional Exhaustion were a high level of job satisfaction and/or enjoyment, and low pay compared to other countries. CONCLUSIONS: Most factors associated with burnout are preventable and can be managed jointly between psychiatrists and administrators. Service providers need to address burnout seriously.